Skip to main content
SpringerLink
Log in

Chemotherapy for Breast Cancer

  • Chapter
Breast Cancer 2nd edition

Part of the book series: M.D. Anderson Cancer Care Series ((MDCCS))

Over the past 30 years, numerous advances have contributed to improved survival for patients with breast cancer. Many of these advances involve the development and use of chemotherapy as adjuvant therapy and for the treatment of metastatic disease. In terms of patient survival, anthracyclinecontaining regimens are superior to non-anthracycline-containing regimens, and regimens containing both an anthracycline and a taxane are superior to regimens containing an anthracycline alone. Anthracyclines and taxanes are the cornerstones of the treatment paradigm employed at M. D. Anderson Cancer Center. This chapter outlines the M. D. Anderson approach to chemotherapy for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • A’Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801–805.

    PubMed  Google Scholar 

  • Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004;22(suppl 14):510.

    Google Scholar 

  • Beslija S, Obralic N, Basic H, et al. A single institution randomized trial of taxotere (T) and Xeloda (X) given in combination vs. taxotere (T) followed by Xeloda (X) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC) [abstract]. Eur J Cancer 2005;(suppl 3):114. Abstract 407.

    Google Scholar 

  • Blum JL, Buzdar AU, LoRusso PM, et al. A multicenter phase II trial of Xeloda (Capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 1998;17:125A. Abstract 476.

    Google Scholar 

  • Burris HA III. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999;26(suppl 9):1–6.

    PubMed  CAS  Google Scholar 

  • Burstein HJ, Younger J, Bunnell CA, et al. Weekly docetaxel (Taxotere) for metastatic breast cancer: a phase II trial [abstract]. Proc Am Soc Clin Oncol 1999;18:127A. Abstract 484.

    Google Scholar 

  • Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212–1219.

    PubMed  CAS  Google Scholar 

  • Buzdar AU, Kau SW, Smith TL, et al. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12:123–128.

    Article  PubMed  CAS  Google Scholar 

  • Buzdar AU, Smith TL, Powell KC, et al. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 1982;2:163–169.

    Article  PubMed  CAS  Google Scholar 

  • Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228–233.

    Article  PubMed  CAS  Google Scholar 

  • Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731–2736.

    PubMed  CAS  Google Scholar 

  • Chen YY, Schnitt SJ. Prognostic factors for patients with breast cancers 1 cm and smaller. Breast Cancer Res Treat 1998;51:209–225.

    Article  PubMed  CAS  Google Scholar 

  • Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490–1495.

    PubMed  CAS  Google Scholar 

  • Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:97A. Abstract 376.

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–942.

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687–1717.

    Article  CAS  Google Scholar 

  • Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993;29A:527–531.

    Article  PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:1669–1676.

    PubMed  CAS  Google Scholar 

  • Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8: 1483–1496.

    PubMed  CAS  Google Scholar 

  • Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.

    PubMed  CAS  Google Scholar 

  • Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439–3460.

    PubMed  CAS  Google Scholar 

  • Gennari A, Sormani MP, Puntoni M, et al. A pooled analysis on the interaction between HER-2 expression and responsiveness of breast cancer to adjuvant chemotherapy [abstract]. Breast Cancer Res Treat 2006;100(suppl 1). Abstract 41.

    Google Scholar 

  • Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002;8:3360–3368.

    PubMed  CAS  Google Scholar 

  • Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004;100:44–52.

    Article  PubMed  Google Scholar 

  • Gradishar W, Krasnojon D, Cheporov S, et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3W solvent-based docetaxel (TXT) as first line therapy of metastatic breast cancer [abstract]. Breast Cancer Res Treat 2006;100(suppl 1). Abstract 46.

    Google Scholar 

  • Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–7803.

    Article  PubMed  CAS  Google Scholar 

  • Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197–2205.

    PubMed  CAS  Google Scholar 

  • Gregory RK, Powles TJ, Chang JC, et al. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997;33:2194–2197.

    Article  PubMed  CAS  Google Scholar 

  • Hanrahan EO, Valero V, Gonzalez-Angulo AM, et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage I; T1a,bN0M0): a review of the literature. J Clin Oncol 2006;24:2113–2122.

    Article  PubMed  Google Scholar 

  • Harvey V, Mouridsen H, Semglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006;24:4963–4970.

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.

    Article  PubMed  CAS  Google Scholar 

  • Holmes FA, Valero V, Walters RS, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 1999;10:403–411.

    Article  PubMed  CAS  Google Scholar 

  • Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797–1805.

    Article  PubMed  CAS  Google Scholar 

  • Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989;63:37–45.

    Article  PubMed  CAS  Google Scholar 

  • Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102 [abstract]. Proc Am Soc Clin Oncol 1998;17. Abstract 1.

    Google Scholar 

  • Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820.

    Article  PubMed  CAS  Google Scholar 

  • Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel for metastatic breast cancer. J Clin Oncol 2005;23:5434–5436.

    Article  Google Scholar 

  • Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091–5097.

    Article  PubMed  Google Scholar 

  • Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932–2947.

    Article  PubMed  CAS  Google Scholar 

  • Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651–2658.

    PubMed  CAS  Google Scholar 

  • Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphomide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21. Abstract 137.

    Google Scholar 

  • Mamounas E, Brown A, Smith R, et al. Effect of taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-h infusion of high-dose taxol [abstract]. Proc Am Soc Clin Oncol 1998;17:101A. Abstract 389.

    Google Scholar 

  • Martin M, Pienkowski T, Mackwy J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–2313.

    Article  PubMed  CAS  Google Scholar 

  • Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005a;23:792–799.

    Article  PubMed  CAS  Google Scholar 

  • Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005b;94(suppl 1):792–799.

    Google Scholar 

  • Muss HB, Case LD, Richards F III, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991;325:1342–1348.

    PubMed  CAS  Google Scholar 

  • Nabholtz JM. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 1999;26(suppl 9):7–13.

    PubMed  CAS  Google Scholar 

  • Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as front line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968–975.

    Article  PubMed  CAS  Google Scholar 

  • Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858–1867.

    PubMed  CAS  Google Scholar 

  • Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 1999;18:127A. Abstract 483.

    Google Scholar 

  • O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812–2823.

    Article  PubMed  CAS  Google Scholar 

  • Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.

    Article  PubMed  CAS  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.

    Article  PubMed  CAS  Google Scholar 

  • Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 1999;85:104–111.

    Article  PubMed  CAS  Google Scholar 

  • Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356–1361.

    Article  PubMed  CAS  Google Scholar 

  • Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083–4107.

    Article  PubMed  CAS  Google Scholar 

  • Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–2792.

    Article  PubMed  CAS  Google Scholar 

  • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.

    Article  PubMed  CAS  Google Scholar 

  • Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991;9:1650–1661.

    PubMed  CAS  Google Scholar 

  • Seidman AD. Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol 1999;26(suppl 8):14–20.

    PubMed  CAS  Google Scholar 

  • Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol 1998;17:98A. Abstract 377.

    Google Scholar 

  • Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin, trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005:94(suppl 1):S5a.

    Google Scholar 

  • Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as first-line chemotherapy for metastatic breast cancer: intergroup trial E1193. J Clin Oncol 2003;21:588–592.

    Article  PubMed  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.

    Article  PubMed  CAS  Google Scholar 

  • Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup E1199 [abstract]. Breast Cancer Res Treat 2005;94(suppl 1):S20. Abstract 48.

    Google Scholar 

  • Stockler M, Wilcken N, Coates A. Chemotherapy for metastatic breast cancer—when is enough enough? Eur J Cancer 1997;33:2147–2148.

    Article  PubMed  CAS  Google Scholar 

  • Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996;39:285–291.

    Article  PubMed  CAS  Google Scholar 

  • Thomas E, Buzdar A, Theriault R, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial [abstract]. Proc Am Soc Clin Oncol 2000;19. Abstract 285.

    Google Scholar 

  • Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886–2894.

    PubMed  CAS  Google Scholar 

  • Winer E, Berry D, Duggan D, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342 [abstract]. Proc Am Soc Clin Oncol 1998;17:101A. Abstract 388.

    Google Scholar 

Download references

Authors
  1. Marjorie C. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA

    Kelly K. Hunt MD

  2. Department of Plastic Surgery, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA

    Geoffrey L. Robb MD

  3. Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA

    Eric A. Strom MD

  4. Department of Stem Cell Transplantation and Cellular Therapy Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA

    Naoto T. Ueno MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media, LLC

About this chapter

Cite this chapter

Green, M.C., Hortobagyi, G.N. (2008). Chemotherapy for Breast Cancer. In: Hunt, K.K., Robb, G.L., Strom, E.A., Ueno, N.T. (eds) Breast Cancer 2nd edition. M.D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/978-0-387-34952-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-34952-7_12

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-34950-3

  • Online ISBN: 978-0-387-34952-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation